Novartis' Phase II study of skin cancer drug sonidegib meets primary endpoint
Novartis has reported that the Phase II study evaluating its investigational oral compound LDE225 (sonidegib) in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of tr… (Source: Drug Development Technology)
Source: Drug Development Technology - February 20, 2014 Category: Pharmaceuticals Source Type: news
Common Antifungal Drug Works in Basal Cell CarcinomaCommon Antifungal Drug Works in Basal Cell Carcinoma
Itraconazole showed anticancer activity in this skin malignancy, which is the most common form of cancer in humans. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 10, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news
Fluorouracil May Boost Invasive Skin Cancer Risk in SomeFluorouracil May Boost Invasive Skin Cancer Risk in Some
Topical fluorouracil may increase the risk of morpheaform basal cell carcinoma (mBCC) in patients with previous skin cancers, according to data from a VA study. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 26, 2013 Category: Dermatology Tags: Hematology-Oncology News Source Type: news
Hedgehog's long snout finds a cure
(Human Frontier Science Program) In 2013 the European Medicines Agency approved a new anti-cancer drug, Erivedge, developed by Genentech and Curis Inc., for the treatment of basal cell carcinoma. This drug is the result of a steady stream of papers that followed the discovery of the SHH gene in the labs of Philip Ingham, Andrew McMahon and Cliff Tabin, the result of a three way transatlantic collaboration funded by HFSP in 1993. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 20, 2013 Category: Cancer & Oncology Source Type: news
Basal Cell Carcinoma: Looks Can Be Deceiving
Basal cell carcinoma often has a distinct appearance: a waxy bump that is pearly or translucent, with a rolled border is classic. But its appearance can raise suspicion for other conditions—mainly melanoma. Here are some examples of typical and atypical BCCs. (Source: Consultant Live)
Source: Consultant Live - October 23, 2013 Category: Primary Care Source Type: news
Skin cancer drug shows periocular promise
Early research suggests that patients with periocular basal cell carcinoma may benefit from treatment with a drug targeting the Hedgehog signaling pathway. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 21, 2013 Category: Cancer & Oncology Source Type: news
Sunscreen shields important anti-cancer gene
Researchers who conducted the world's first study to assess the molecular impact of sunscreen found it offers 100% protection against all three types of skin cancer - basal cell carcinoma, squamous cell carcinoma and malignant melanoma. They also found sunscreen prevents damage to a key anti-cancer gene known as p53. There is lots of evidence that sunscreen stops skin from getting sunburn, but not much is known - although there is much speculation - about whether it can prevent skin cancers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 10, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
Lichenoid Keratosis
Diagnostic possibilities for this asymptomatic “red spot” included squamous cell carcinoma in-situ, superficial basal cell carcinoma, lichenoid keratosis, and insect bite. This case underscores the importance of a biopsy when the diagnosis is in doubt. (Source: Consultant Live)
Source: Consultant Live - September 11, 2013 Category: Primary Care Source Type: news
First-of-a-kind once daily pill given regulatory green light for patients with rare type of skin cancer, UK
Patients with advanced basal cell carcinoma who are not suitable for surgery or radiotherapy, could benefit from Erivedge (vismodegib) which is available following conditional EMA authorisation for use in the UK and listing on the national Cancer Drugs Fund (CDF).*[1],[2] Basal cell carcinoma (BCC) is the most common form of skin cancer in the UK[3],[4] and is often found on the head and neck... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
Skin cancer drug approved by UK regulators
Roche’s skin cancer drug, Erivedge (vismodegib), has been approved by regulators to treat people with severe basal cell carcinoma (BCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 11, 2013 Category: Pharmaceuticals Source Type: news
Squamous Cell Carcinoma In-Situ
Eccentric and irregular pigmentation prompted a biopsy in this elderly woman with a history of basal cell carcinoma and melanoma. The surprising diagnosis was a heavily pigmented squamous cell carcinoma in-situ. (Source: Consultant Live)
Source: Consultant Live - July 29, 2013 Category: Primary Care Source Type: news
Roche Gets Conditional EU Approval for Basal Cell Carcinoma DrugRoche Gets Conditional EU Approval for Basal Cell Carcinoma Drug
Roche said it had received conditional approval from the European Commission for Erivedge (vismodegib), for adults with metastatic BCC or locally advanced BCC inappropriate for surgery or radiotherapy. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 15, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Roche's Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer
Roche announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. This approval makes Erivedge, a capsule taken once-a-day, the first licensed medicine for patients in the European Union with this disfiguring and potentially life-threatening form of skin cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 15, 2013 Category: Pharmaceuticals Source Type: news
Roche's Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer.
Roche announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. (Source: Roche Media News)
Source: Roche Media News - July 15, 2013 Category: Pharmaceuticals Source Type: news
Roche gets Swiss approval for skin cancer drug
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG has received Swiss approval for Erivedge, the first medicine for people with advanced forms of basal cell carcinoma, the most common skin cancer. (Source: Reuters: Health)
Source: Reuters: Health - June 11, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
